Usefulness of 22-oxa-1,25-dihydroxyvitamin D3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors

International Journal of Oncology

Volumn 9, Issue 1, 1996, Pages 79-82

  Andoh, Tatsumasa ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

22 oxa 1; 25 dihydroxyvitamin D3; Combined therapy; DMBA induccd rat mammary tumor

Indexed keywords

AROMATASE INHIBITOR; CALCITRIOL; FADROZOLE; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0029896415     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.1.79     Document Type: Article

References (5)

1. 3. Proc Natl Acad Sci USA 78: 4990-4994, 1981.
2. Tanaka H, Abe E, Miyaura C, et al: 1α, 25-dihydroxycholecalciferol and human myeloid leukemia cell line (HL-60). Biochem J 204: 713-719, 1982.
3. Olsson I, Gullberg U, Ivhed I, et al: Induction of differentiation of the human histiocytic lymphoma cell line U-937 by la, 25-dihydroxycholecalciferol. Cancer Res 43: 5862-5867, 1983.
4. 3 in the murine myelocytic leukemia. Cancer Res 46: 6316-6321, 1986.
5. 3 receptors in established human cancer cell lines in culture. Cancer Res 42: 1116-1119, 1982.